Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Psychosis and schizophrenia in adults: prevention and management

Psychosis and schizophrenia in adults: prevention and management Psy Psychosis and schizophrenia in adults: chosis and schizophrenia in adults: pre prev vention and management ention and management Clinical guideline Published: 12 February 2014 nice.org.uk/guidance/cg178 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in adults: prevention and management (CG178) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

162. Schizophrenia: aripiprazole prolonged-release suspension for injection

Schizophrenia: aripiprazole prolonged-release suspension for injection Schizophrenia: aripipr Schizophrenia: aripiprazole prolonged-release azole prolonged-release suspension for injection suspension for injection Evidence summary Published: 26 March 2014 nice.org.uk/guidance/esnm39 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (...) (BNF) or the MHRA or NICE websites for up-to-date information. Summary Aripiprazole prolonged-release suspension for injection is licensed for maintenance treatment of schizophrenia in adults whose condition has been stabilised with oral aripiprazole. It was launched in the UK in January 2014. In 2 double-blind, randomised controlled trials (RCTs; n=403 and n=662), once-monthly aripiprazole 400 mg prolonged-release injection was shown to be superior to placebo and non-inferior to oral aripiprazole

2014 National Institute for Health and Clinical Excellence - Advice

163. Schizophrenia: lurasidone

Schizophrenia: lurasidone Schizophrenia: lur Schizophrenia: lurasidone asidone Evidence summary Published: 23 September 2014 nice.org.uk/guidance/esnm48 pathways This advice replaces ESNM15. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Lurasidone (Latuda, Sunovion (...) Pharmaceuticals Europe Ltd) is licensed for treating schizophrenia in adults aged 18 years and over. It was launched in the UK in August 2014. Evidence from 5 short- term and 3 long-term studies suggests that lurasidone is effective at treating psychotic symptoms, and at preventing relapse in adults with schizophrenia. The European Public Assessment Report [EPAR] for lurasidone states that the adverse event profile of lurasidone is similar to that for other second-generation antipsychotics, the most common

2014 National Institute for Health and Clinical Excellence - Advice

164. Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting

Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting Community-based intervention for people with schizophrenia successfully provided by supervised community health workers in a low-resource setting | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Community-based intervention for people with schizophrenia successfully provided by supervised

2014 Evidence-Based Mental Health

165. Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered

Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different side effects should be considered | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paliperidone depot is not different from haloperidol in relapse prevention of schizophrenia, but different

2014 Evidence-Based Mental Health

166. Metformin for weight loss in schizophrenia: safe but not a panacea

Metformin for weight loss in schizophrenia: safe but not a panacea Metformin for weight loss in schizophrenia: safe but not a panacea | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin for weight loss in schizophrenia: safe but not a panacea Article Text Pharmacological interventions Metformin for weight loss in schizophrenia: safe but not a panacea Cenk Tek 1 , Lydia Chwastiak 2 Statistics from Altmetric.com What is already

2014 Evidence-Based Mental Health

167. Case control study: People with schizophrenia are more likely to have a mother who smoked during pregnancy than people without the condition Full Text available with Trip Pro

to genetic factors, environmental factors may play a role in the aetiology of psychotic disorders, and PTE has been considered as having a potential influence on developing psychotic disorders. In the current study, Stathopoulou and colleagues examined the association between prenatal smoking behaviours of mothers of schizophrenic and non-schizophrenic patients. The purpose of their study was to determine if there was an association between PTE and the risk of schizophrenia and the severity (...) of schizophrenic symptomatology. Methods Between 2002 and 2008, 212 schizophrenic inpatients and outpatients were recruited into the study. Diagnoses were determined from a structured clinical interview. A further 212 individuals were included as controls. Control subjects were matched on sex, age, educational level and place of residence. PTE was assessed retrospectively by asking both parents about smoking during pregnancy. Statistical analyses of the data included testing reliability of the schizophrenia

2014 Evidence-Based Nursing

168. Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines

for schizophrenia: clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT3 Receptor Antagonistss Language Published English Country (...) Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-term 5HT3 antagonist use

2014 Health Technology Assessment (HTA) Database.

169. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. Full Text available with Trip Pro

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has not been assessed.To compare the effectiveness of the second-generation long-acting injectable antipsychotic (...) paliperidone palmitate with the older long-acting injectable antipsychotic haloperidol decanoate.Multisite, double-blind, randomized clinical trial conducted from March 2011 to July 2013 at 22 US clinical research sites. Randomized patients (n = 311) were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to be at risk of relapse and likely to benefit from a long-acting injectable antipsychotic.Intramuscular injections of haloperidol decanoate 25 to 200 mg

2014 JAMA Controlled trial quality: predicted high

170. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. (Abstract)

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Treatment of schizophrenia depends heavily on neuroleptic drugs. Hypersalivation is a common side effect when people with schizophrenia are treated with neuroleptic drugs. Hypersalivation can be an embarrassing and stigmatising problem, can affect quality of life and can result in discontinuation of neuroleptic treatment. It can also be difficult to treat.To summarise the best (...) available evidence of the effects of anticholinergic drugs in the treatment of non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Clozapine-induced hypersalivation has been addressed in another Cochrane review.We searched the Cochrane Schizophrenia Group Trials Register (15 November 2012) and inspected references of all identified studies for further relevant studies. We were to contact the first author of each included study for information regarding unpublished trials.All

2013 Cochrane

171. Schizophrenia: an integrated sociodevelopmental-cognitive model. Full Text available with Trip Pro

Schizophrenia: an integrated sociodevelopmental-cognitive model. Schizophrenia remains a major burden on patients and society. The dopamine hypothesis attempts to explain the pathogenic mechanisms of the disorder, and the neurodevelopmental hypothesis the origins. In the past 10 years an alternative, the cognitive model, has gained popularity. However, the first two theories have not been satisfactorily integrated, and the most influential iteration of the cognitive model makes no mention (...) of salience to stimuli, which are then misinterpreted by the biased cognitive processes. The resulting paranoia and hallucinations in turn cause further stress, and eventually repeated dopamine dysregulation hardwires the psychotic beliefs. Finally, we consider the implications of this model for understanding and treatment of schizophrenia. Copyright © 2014 Elsevier Ltd. All rights reserved.

2013 Lancet

172. Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor Full Text available with Trip Pro

Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy (...) for positive and negative symptoms and cognition. Another method to enhance NMDA function is to raise the levels of d-amino acids by blocking their metabolism. Sodium benzoate is a d-amino acid oxidase inhibitor.To examine the clinical and cognitive efficacy and safety of add-on treatment of sodium benzoate for schizophrenia.A randomized, double-blind, placebo-controlled trial in 2 major medical centers in Taiwan composed of 52 patients with chronic schizophrenia who had been stabilized with antipsychotic

2013 EvidenceUpdates Controlled trial quality: predicted high

173. Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work (Abstract)

Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work People with psychiatric impairments (primarily schizophrenia or a mood disorder) are the largest and fastest-growing group of Social Security Disability Insurance (SSDI) beneficiaries. The authors investigated whether evidence-based supported employment and mental health treatments can improve vocational and mental health recovery for this population.Using (...) measures.Overall, 2,059 SSDI beneficiaries with schizophrenia, bipolar disorder, or depression in 23 cities participated in the 2-year intervention. The teams implemented the intervention package with acceptable fidelity. The intervention group experienced more paid employment (60.3% compared with 40.2%) and reported better mental health and quality of life than the control group.Implementation of the complex intervention in routine mental health treatment settings was feasible, and the intervention

2013 EvidenceUpdates Controlled trial quality: uncertain

174. Dance therapy for schizophrenia. (Abstract)

Dance therapy for schizophrenia. Dance therapy or dance movement therapy (DMT) is defined as 'the psychotherapeutic use of movement as a process which furthers the emotional, social, cognitive, and physical integration of the individual'. It may be of value for people with developmental, medical, social, physical or psychological impairments. Dance therapy can be practiced in mental health rehabilitation units, nursing homes, day care centres and incorporated into disease prevention and health (...) promotion programmes.To evaluate the effects of dance therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care and other interventions.We updated the original July 2007 search of the Cochrane Schizophrenia Group' register in July 2012. We also searched Chinese main medical databases.We included one randomised controlled trial (RCT) comparing dance therapy and related approaches with standard care or other psychosocial interventions for people

2013 Cochrane

175. Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. (Abstract)

Randomized Controlled Trial Research Support, Non-U.S. Gov't China Hong Kong Med J 9512509 1024-2708 IM Adolescent Adult Affect Asian Continental Ancestry Group psychology Cognition Computer-Assisted Instruction Double-Blind Method Female Hong Kong Humans Language Male Middle Aged Personality Inventory Psychiatric Status Rating Scales Rehabilitation, Vocational methods Schizophrenia rehabilitation Schizophrenic Psychology Self Efficacy Thinking Young Adult 2012 12 20 6 0 2013 4 12 6 0 2013 10 1 6 0 (...) Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. 23249847 2013 09 30 2016 10 20 1024-2708 18 Suppl 6 2012 Dec Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Cognitive training for Hong Kong Chinese with schizophrenia in vocational rehabilitation. 18-22 Man D W K DW Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China. David.Man@polyu.edu.hk Law K M KM Chung R C K RC eng Journal Article

2013 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

176. Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial Full Text available with Trip Pro

Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial Quality of life (QoL) measurements are increasingly considered to be an important evaluation of the treatment and care provided to patients with schizophrenia. However, there is little evidence that assessing QoL improves patient outcomes in clinical practice.To investigate the impact of a QoL assessment with feedback for clinicians regarding satisfaction (...) and other health outcomes in patients with schizophrenia.We conducted a 6-month, prospective, randomised and controlled open-label study. Patients with schizophrenia were assigned to one of three groups: standard psychiatric assessment; QoL assessment with standard psychiatric assessment; and QoL feedback with standard psychiatric assessment. The primary outcome was patient satisfaction at 6 months. The local ethics committee (Comité de Protection des Personnes Sud-Méditerranéee V, France, trial number

2013 EvidenceUpdates Controlled trial quality: uncertain

177. The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: A randomised controlled trial with 24-month follow-up Full Text available with Trip Pro

The effectiveness of mutual support group intervention for Chinese families of people with schizophrenia: A randomised controlled trial with 24-month follow-up Positive effects on the relapse from illness and compliance with medication by patients have been observed from family intervention for schizophrenia. However, little attention has been paid to the effects on family members, particularly those in non-Western countries. Inconsistent and inconclusive findings were found on the family (...) -related outcomes and longer-term effects of family intervention.This study tested the effects of a nine-month family-led mutual support group for Chinese people with schizophrenia, compared with a psycho-education group and standard psychiatric care over a 24-month follow-up.A randomised controlled trial [registered with ClinicalTrials.gov (NCT00940394)] with repeated-measures, three-group design.Two regional psychiatric outpatient clinics in Hong Kong.One hundred and thirty-five Chinese family

2013 EvidenceUpdates Controlled trial quality: uncertain

178. Nidotherapy for people with schizophrenia. Full Text available with Trip Pro

Nidotherapy for people with schizophrenia. Nidotherapy is a therapeutic method that principally aims to modify the environment of people with schizophrenia and other serious mental illnesses, whilst working in conjunction with, or alongside other treatments. Rather than focusing on direct treatments or interventions, the aim is to help the individual identify the need for, and work to effect environmental change with the aim of minimising the impact of any form of mental disorder (...) on the individual and society.To review the effects of nidotherapy added to standard care, compared with standard care or no treatment for people with schizophrenia or related disorders.We searched the Cochrane Schizophrenia Group Trials Register (December 2011) and supplemented this by contacting relevant study authors, handsearching nidotherapy articles and manually searching reference lists.All randomised controlled trials (RCTs) that compared nidotherapy with standard care or no treatment.We independently

2013 Cochrane

179. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

180. Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study (Abstract)

Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study Schizophrenia is associated with premature mortality, but the specific causes and pathways are unclear. The authors used outpatient and inpatient data for a national population to examine the association between schizophrenia and mortality and comorbidities.This was a national cohort study of 6,097,834 Swedish adults, including 8,277 with schizophrenia, followed for 7 years (2003-2009) for mortality (...) and comorbidities diagnosed in any outpatient or inpatient setting nationwide.On average, men with schizophrenia died 15 years earlier, and women 12 years earlier, than the rest of the population, and this was not accounted for by unnatural deaths. The leading causes were ischemic heart disease and cancer. Despite having twice as many health care system contacts, schizophrenia patients had no increased risk of nonfatal ischemic heart disease or cancer diagnoses, but they had an elevated mortality from ischemic

2013 EvidenceUpdates